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Renal disease will affect around 40% of  people with type 2 diabetes (T2D) and is a leading 
cause of morbidity and mortality(1).Management of Diabetic Kidney Disease (DKD) has 
traditionally  focused on tight glycaemic  (in the early stages ) and blood pressure control the 
latter including agents which inhibit the renin-angiotensin system(1).Despite this, most 
patients with DKD experience  a gradual decline in renal function eventually progressing to 
end stage renal disease and an increased risk of cardiovascular events and mortality. 
Glucagon like peptide-1 receptor agonists (GLP1-RAs) are  established treatments for T2D 
which, in addition to glucose lowering, are associated with weight loss, blood pressure 
lowering and cardio-protection (2).  There is a lack of clarity, however, on the long-term 
benefits of GLP-1RA therapy in DKD particularly in relation to glomerular function. 
 
In their paper published in the Lancet D and E, Mann et al (3), report a post-hoc analysis  of 
changes over a period of 30 weeks in glomerular function, albuminuria and safety  from 
pooled data from SUSTAIN (1-5 and 7) studies and then separately from the longer term 
Cardiovascular Outcome Trial-SUSTAIN 6 (4). The GLP-1 RA, semaglutide, was associated 
with : (a) a fall  in eGFR of 2.5 to 3.5ml/min during the  first 12 weeks  followed by  
stabilisation  between 12-30 weeks in those with baseline eGFR >60ml/min, but less marked 
in those with significant renal impairment (b) a consistent and significant decrease in 
albuminuria more  pronounced  in those with established albuminuria (c) no excess risk of 
major renal adverse events including  acute renal injury or urinary disorders.  
 
Currently, most   evidence for renal protection with  GLP1-RAs comes  from  cardiovascular 
outcome trials (CVOTs)(5-7). Pre-specified sub-group analysis of data from these studies 
have shown an overall reduction in composite renal outcomes (incidence and progression of 
albuminuria, doubling of serum creatinine, requirement for renal replacement therapy and 
renal death). The reported benefits  were mainly driven by a gradual reduction in albuminuria 
with only a minimal effect on glomerular function. The more acute fall in eGFR followed by 
evidence of stabilisation  reported by Mann et al and seen in each of the individual SUSTAIN 
trials is  surprising and  not previously noted  with GLP1-RA therapy.  
Haemodynamic alterations following treatment with renin angiotensin and SGLT2 inhibitors 
are well recognized(8) .The resulting decrease in glomerular pressure has been associated 
with prevention and/or reduction of  albuminuria and delay in progression of DKD. This is 
therefore an area of significant interest in relation to GLP-1 RA therapy where the LEADER 
trial (6)and the exploratory analysis of the REWIND study(5) have previously reported 
significant reductions in albuminuria independent of glycaemic and blood pressure control 
with liraglutide and dulaglutide respectively.  The findings of the present study  suggest a 
similar reduction in albuminuria with semaglutide. Given that increasing levels of 
albuminuria are  poor prognostic markers in DKD, such reductions in albuminuria with GLP-
1 RAs are of interest, but emphasise the need for more studies to determine whether this is 
reflected in renal protection long term.  
 
Whilst the inclusion of a large number of subjects and the consistency of the findings can be 
seen as a strength, a  major limitation of this post-hoc analysis  is that it is based on data 
pooled from different studies. This  imposes restrictions on analysis and interpretation of the 
findings. For example, there is  a significant degree of heterogeneity between the cohorts  
plus varying durations of follow up. Moreover, limiting duration of follow up to   only 30 
weeks is insufficient  to provide information on  the effects of semaglutide on progression of 
DKD and indeed on long term safety.  It could be argued, however,  that given the patient 
cohorts include those with  large ranges of eGFR and albuminuria, this  allows for a better 
understanding of the effects of semaglutide at different stages and severity of DKD. In 
addition, the findings that semaglutide  was not associated with an increase in renal adverse 
events and particularly acute kidney injury or urinary disorders  provide reassurance 
regarding its use for its primary indications.  
 
Whilst these findings may be seen as highly relevant in the context of management  of T2D 
and specifically in prevention and progression of associated DKD, significant questions 
remain.  Reductions in albuminuria and hemodynamic changes affecting  glomerular function 
are recognised markers indicating reno-protection, but DKD progresses over many years and 
there is little evidence whether these improvements will translate into reduction of  
progression to ESRD. Hopefully this  critical point will be answered by the ongoing renal 
outcome studies such as Semaglutide Renal Outcomes Trial (FLOW).  
 
Another question relates to establishing the role and positioning of GLP1-RA treatment in the 
management of DKD.  For example, an agent from a different class of anti-diabetes therapies, 
the SGLT-2 inhibitor canagliflozin,  effectively improves all renal outcomes (9) and studies 
involving others in the class indicating similar benefits (10). To more clearly define the place 
of these agents in management, an understanding of the  exact mechanisms through which 
SGLT2i and GLP1-RA exert their renal  effects needs  to be elucidated. If the mechanisms 
are different, could they have a complimentary role?  Finally, despite the limitations of this 
type of analysis, these findings  offer  some reassurance and confidence in  the use of GLP1-
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